Spots Global Cancer Trial Database for immune system diseases
Every month we try and update this database with for immune system diseases cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Research on the Application and Mechanism of New Biological Probes in Biomedicine | NCT04977739 | Tumors Cardiovascular ... Respiratory Sys... Digestive Syste... Endocrine Syste... Metabolic Disea... Immune System D... Urinary System ... Nervous System ... Blood Diseases Infectious Dise... | No intervention | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| Exploring Outcomes and Characteristics of Myasthenia Gravis 2 | NCT06002945 | Myasthenia Grav... | Blood sample | 18 Years - | Yale University | |
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | NCT00779883 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT03373019 | Chidamide Lymphoma, B-Cel... Lymphoma, Large... Neoplasm by His... Neoplasms Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... Lymphoma, Non-H... Cyclophosphamid... Rituximab Gemcitabine Cisplatin Dexamethasone HDAC Inhibitor | Chidamide combi... | 18 Years - 75 Years | Fudan University | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Research on the Application and Mechanism of New Biological Probes in Biomedicine | NCT04977739 | Tumors Cardiovascular ... Respiratory Sys... Digestive Syste... Endocrine Syste... Metabolic Disea... Immune System D... Urinary System ... Nervous System ... Blood Diseases Infectious Dise... | No intervention | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis | NCT05917184 | Myasthenia Grav... | Telehealth | 18 Years - | Yale University | |
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | NCT00779883 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes | NCT02134262 | Relapsed or Ref... | Cyclophosphamid... Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3 | 20 Years - 70 Years | Jichi Medical University | |
| Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy | NCT02765594 | Primary IgA Nep... | Hydroxychloroqu... Valsartan | 18 Years - 60 Years | Peking Union Medical College Hospital | |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia | NCT02733042 | Lymphoma Leukemia, Lymph... | Durvalumab Lenalidomide Rituximab Ibrutinib Bendamustine | 18 Years - | Celgene | |
| A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | NCT04104776 | Advanced Solid ... Diffuse Large B... Lymphoma, T-Cel... Mesothelioma, M... Prostatic Neopl... Endometrial Can... Ovarian Clear C... | CPI-0209 | 18 Years - | Constellation Pharmaceuticals | |
| Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy | NCT01435356 | Urinary Bladder... | recMAGE-A3 + AS... Placebo | 18 Years - | European Association of Urology Research Foundation | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Research on the Application and Mechanism of New Biological Probes in Biomedicine | NCT04977739 | Tumors Cardiovascular ... Respiratory Sys... Digestive Syste... Endocrine Syste... Metabolic Disea... Immune System D... Urinary System ... Nervous System ... Blood Diseases Infectious Dise... | No intervention | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms | NCT06065592 | Cancer Solid Tumor Thromboembolism Cardiovascular ... Immune System D... Inflammatory Di... Colon Cancer Breast Cancer Prostate Cancer Hepatocellular ... Lung Cancer Chemotherapy Immunotherapy | Palbociclib Rivaroxaban SNP | 18 Years - | Lebanese University | |
| Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | NCT05066165 | Acute Myeloid L... | Arm 1: NTLA-500... Arm 2: NTLA-500... | 18 Years - | Intellia Therapeutics | |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | NCT01183949 | Multiple Myelom... | AT7519M Bortezomib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT | NCT02627573 | Leukemia, Chron... Myelodysplastic... Leukemia, Myelo... | Unrelated allog... Busulfan Fludarabine mon... Tacrolimus Mycophenolate m... Cyclophosphamid... Thymoglobulin | 18 Years - 75 Years | St. Petersburg State Pavlov Medical University | |
| Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) | NCT02657447 | Non-Hodgkin Lym... | Betalutin with ... Betalutin with ... | 18 Years - | Nordic Nanovector | |
| Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | NCT02294552 | Acute Myeloid L... Acute Lymphoid ... Lymphoma Myelodysplastic... Chronic Lymphoc... Immune System D... | Cyclophosphamid... Busulfan Fludarabine mon... Tacrolimus Mycophenolate m... Allogeneic hema... | 18 Years - 65 Years | St. Petersburg State Pavlov Medical University | |
| A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT05431179 | Lymphoma, Mantl... Lymphoma Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... Lymphoma, Non-H... Lymphoma, B-Cel... | Zilovertamab Ibrutinib Placebo | 18 Years - | Oncternal Therapeutics, Inc | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | NCT02112526 | Activated B-cel... | Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | NCT01063907 | Multiple Myelom... | KW-2478 Bortezomib | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma | NCT03672318 | Multiple Myelom... Immune System D... | CAR138 T Cells | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | NCT02690545 | Lymphoma Lymphoma, Non-H... Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Neoplasms by Hi... | ATLCAR.CD30 cel... | 3 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | NCT02799147 | Leukemia, Acute... Acute Myeloid L... Mixed-Lineage A... | Allogeneic stem... Fludarabine mon... Busulfan Bendamustine | 18 Years - 60 Years | St. Petersburg State Pavlov Medical University | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | NCT00773747 | Multiple Myelom... | Vorinostat bortezomib placebo to vori... | 18 Years - | Merck Sharp & Dohme LLC | |
| Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | NCT03016377 | Acute Lymphobla... Immune System D... Immunoprolifera... | iC9-CAR19 cells Rimiducid Cyclophosphamid... Fludarabine | 3 Years - 70 Years | UNC Lineberger Comprehensive Cancer Center | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis | NCT05451212 | MuSK Myasthenia... | MuSK-CAART | 18 Years - | Cabaletta Bio | |
| Lymphoma Epidemiology of Outcomes Cohort Years 6-10 | NCT04996706 | Lymphoma, Non-H... | 18 Years - | Mayo Clinic | ||
| SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | NCT00365274 | Anaplastic Larg... | Cyclophosphamid... Doxorubicin hyd... vincristine sul... prednisone SGN-30 | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE | NCT04258683 | Multiple Myelom... | Pembrolizumab | 18 Years - | Canadian Myeloma Research Group | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms | NCT06065592 | Cancer Solid Tumor Thromboembolism Cardiovascular ... Immune System D... Inflammatory Di... Colon Cancer Breast Cancer Prostate Cancer Hepatocellular ... Lung Cancer Chemotherapy Immunotherapy | Palbociclib Rivaroxaban SNP | 18 Years - | Lebanese University | |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | NCT04904588 | Acute Lymphobla... Acute Myelogeno... Mixed Phenotype... Acute Leukemia Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Lymphoma | Busulfan Busulfan Fludarabine Total-body irra... Cyclophosphamid... Melphalan PBSC Hematopoie... Bone Marrow Hem... Post-transplant... Mesna Tacrolimus Mycophenolate M... Patient-Reporte... | 1 Year - | Center for International Blood and Marrow Transplant Research | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | NCT01990534 | Hodgkin Lymphom... | Brentuximab Ved... | 18 Years - | Takeda | |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | NCT04996875 | Advanced System... SM With an Asso... Mast Cell Leuke... Aggressive Syst... | bezuclastinib | 18 Years - | Cogent Biosciences, Inc. | |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | NCT01183949 | Multiple Myelom... | AT7519M Bortezomib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | NCT02663297 | Hodgkin Disease Lymphoma Lymphoma, Non-H... Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Neoplasms by Hi... | ATLCAR.CD30 cel... | 3 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL | NCT00772486 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT03155191 | Lymphoblastic L... | TBI-1501 | 16 Years - | Takara Bio Inc. | |
| A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL | NCT00772486 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| A Phase I Extension Trial of Repeated Infusions of ISF35 | NCT00783588 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | NCT05186753 | SSM Mastocytosis, I... Mastocytosis, S... Mastocytosis | Bezuclastinib T... Bezuclastinib T... Placebo Tablets | 18 Years - | Cogent Biosciences, Inc. | |
| Lymphoma Epidemiology of Outcomes Cohort Years 6-10 | NCT04996706 | Lymphoma, Non-H... | 18 Years - | Mayo Clinic | ||
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
